Comparison

AMGEN INC (AMGN) vs Elanco Animal Health Inc (ELAN)

The same filed metrics for both companies, side by side.

What each names as a risk in its own annual report, how each is priced against its own history, and the tracked managers whose latest 13F reports a position in both.

Financials

AMGN

AMGEN INC

Drug Manufacturers—General

Revenue, FY25: $36.75B
Net income: $7.71B
Operating cash flow: $9.96B
Free cash flow: $8.1B
Net margin: 20.98%
Operating margin: 24.71%
Gross margin: 67.25%

ELAN

Elanco Animal Health Inc

Drug Manufacturers—Specialty & Generic

Revenue, FY25: $4.72B
Net income: −$232M
Operating cash flow: $560M
Free cash flow: $284M
Net margin: −4.92%
Operating margin: -
Gross margin: 54.99%

Head-to-head

Filed growth, quality and valuation, read against each company’s own history rather than against the other side.

Metric	AMGN	ELAN
Revenue growth, latest filed year	+9.95%	+6.22%
Piotroski F-score	7 of 9	5 of 9
P/E against its own history	about normal	-

What each says it is exposed to

From Item 1A of each company’s most recent 10-K.

AMGN

FDA approval
Reimbursement
Cybersecurity
Litigation
China
Tax

And 20 more.

ELAN

Debt covenants
Currency moves
Tariffs
Litigation
Goodwill impairment
Product recalls

And 19 more.

Tracked managers holding both

Dodge & Cox Dodge & Cox 0.00% · 0.87%
Joel Greenblatt Gotham Asset Management 0.04% · 0.03%

Updated Aug 5, 2026 · the newer of the two companies' filings